Ignite Creation Date:
2024-05-05 @ 9:39 PM
Last Modification Date:
2024-10-26 @ 10:07 AM
Study NCT ID:
NCT00932126
Status:
TERMINATED
Last Update Posted:
2015-10-28
First Post:
2009-06-30
Brief Title:
This Is The First Study Using Escalating Doses Of PF-03758309 An Oral Compound In Patients With Advanced Solid Tumors
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 1 Open Label Dose-Escalation Safety Pharmacokinetic And Pharmacodynamic Study Of Single Agent PF-03758309 An Oral PAK4 Inhibitor In Patients With Advanced Solid Tumors
Status:
TERMINATED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
See termination reason in detailed description
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is the first study using PF-03758309 an oral compound in patients with advanced solid tumors In this study different doses of PF-03758309 will be administered to different groups of patients The study will assess the compounds safety the blood levels of PF-03758309 during the treatment and the effect of the compound on the tumor cells
Detailed Description:
The study was prematurely terminated on 26Jul2011 due to the undesirable PK characteristics of PF-03758309 and the lack of an observed dose-response relationship There were no safety concerns that contributed to the study termination
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None